Pubblicazioni 
Pubblicazioni
Tumori della vescica
Urologia Endoscopica
Urologia Funzionale
Infezioni UTI
Andrologia IPP
Urologia pediatrica
list of publicationsFunzionale.pdf
list of publicationsIPP.pdf
Urologia Funzionale
1. Fontanella UA, et al. Iontophoretic Local Anaeshesia for Bladder Dilatation in the Treatment of Interstitial Cystitis. Br J Urol., 1992; 69 (6): 662-663.2. Lugnani F, et al. Iontophoresis of drugs in the bladder wall: equipment and preliminary studies. Art Org 1993; 171 (1): 8-17.3. Gürpinar T, et al. Electromotive drug administration to the urinary bladder: an animal model and preliminary results. J Urol 1996; 156: 1496-1501. 4. Gürpinar T, et al. Electromotive administration of intravesical lidocaine in patients with interstitial cystitis. J Endourol; 1996; 10 (5): 443-447.5. Fontanella UA, et al. Bladder and urethral anaesthesia with electromotive drug administration (EMDA): an adequate technique for invasive endoscopic procedures. Br J Urol 1997; 79: 414-420.6. Rosamilia A, et al. Electromotive drug administration of lidocaine and dexamethasone followed by cystodistension in women with interstitial cystitis. Int Urogynecol J 1997; 8: 142-145.7. Riedl CR, et al. Intravesical electromotive drug administration for the treatment of non-infectious chronic cystitis. Int Urogynecol 1997; 8: 134-137.8. Di Stasi S, et al. Electromotive administration of oxybutynin into the human bladder wall. J Urol 1997; 158: 228-233.9. Dasgupta P, et al. Electromotive drug administration of lidocaine to anesthetize the bladder before intravesical capsaicin. J Urol 1998; 159: 1857-1861.10. Riedl CR, et al. Electromotive drug administration and hydrodistension for the treatment of interstitial cystitis. J Endourol 1998; 12 (3): 269-272.11. Riedl CR, et al. Intravesical electromotive drug administration technique: preliminary results and side effects. J Urol 1998; 159: 1851-1856.12. Jewett MAS, et al. Electromotive drug administration of lidocaine as an alternative anesthesia for transurethral surgery. J Urol 1999; 161: 482-485.13. Riedl CR, et al. Electromotive administration of intravesical bethanechol and the clinical impact on acontractile detrusor management: introduction of a new test. J Urol 2000, 164: 2108-2111.14. Di Stasi SM, et al. Intravesical electromotive administration of oxybutynin in patients with detrusor hyperreflexia unresponsive to standard anticholinergic regimens. J Urol 2001, 165: 491-498.15. Di Stasi SM, et al. Intravesical oxybutynin: mode of action assessed by passive diffusion and electromotive administration with pharmacokinetics of oxybutynin and N-desethyl oxybutynin. J Urol 2001, 166: 2232-2236.16. Di Stasi SM et al. The stability of lidocaine and epinephrine solutions exposed to electric current and comparative administration rates of the two drugs into pig bladder wall. Urol Res 2003, 31: 169-176.17. Rose AE, Payne CK and Azevedo K. Pilot studyof the feasibility of In-Office bladder distension using Electromotive Drug Administration (EMDA). Neur and Urodyn 24: 1 7, 2005.18. Rose AE, Azevedo K and Payne CK. Office bladder distension with Electromotive Drug Administration (EMDA) is equivalent under General Anesthesia (GA). BMC Urology 2005, 5:14
Andrologia IPP
1. Riedl CR, et al. Iontophoresis for treatment of Peyronies disease. J Urol 2000; 163: 95-99.2. Montorsi F, et al. Transdermal electromotive multi-drug administration for Peyronie's disease: preliminary results. J Andrology 2000; 21 (1): 85-903. Levine LA et al. Tunica albuginea tissue analysis after electromotive drug administration. J Urol 2003, 169: 1775-1778.4. Di Stasi SM et al. Transdermal electromotive administration of verapamil and dexamethasone for Peyronies disease. BJU Intl 2003, 91: 825-829.5. Di Stasi SM et al. A prospective randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronies disease. J Urol 2004, 174: 1605-1608.
list of publicationsOnco.pdf
Tumori della vescica
1. Di Stasi S, et al. Electromotive delivery of Mitomycin C into human bladder wall. Cancer Res 1997; 57: 875-880.2. Brausi M, et al. Intravesical electromotive administration (EMDA) of drugs for treatment of superficial bladder cancer: a comparative phase II study. Urol 1998; 51 (3): 506-509.3. Di Stasi SM, et al. Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies. Cancer Res 1999; 59: 4912-4918.4. Di Stasi SM et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomised study. J Urol 2003, 170: 777-782.5. Di Stasi SM et al. Percutaneous sequential bacillus Calmette-Guèrin and mitomycin C for panurothelial carcinomatosis. Can J Urol 2005, 12(6): 2895-28986. Di Stasi SM et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. The Lancet Oncol 2006, 7: 43-517. Di Stasi SM, Riedl C: Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer. World J Urol, published on line on 21 February 20098. Di Stasi SM et al. ; Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. The Lancet Oncology 2011
Patient Info Urinary bladder cancer
Cancer of the urinary bladder is the fourth most common malignancy among men, and the eighth most frequent among women. An average of 260,000 new cases of urinary bladder cancer are diagnosed worldwide every year.
Approximately 90% of these cancers are of "Transitional Cell Carcinoma" (TCC) type, originating in the epithelial cells (the internal lining) of the bladder wall.
When the tumor is limited to this layer, it is called "Non-Muscle invasive" (superficial) urinary bladder cancer. This superficial type of cancer tends to recur despite surgery and/or treatment; in most cases, the tumor tends to recur as Non-Muscle invasive cancer.
A tumor that penetrates more deeply into the muscular layer of the urinary bladder, is called "invasive" urinary bladder cancer
Symptoms of the disease
The symptoms of urinary bladder cancer, which are not necessarily evident, generally include:
Presence of blood in urine (hematuria); the passing of bloody urine is generally painless
Blood traces in urine laboratory tests
Urgency (inability to postpone urination) and frequency (urinating often)
Discomfort during urination
These symptoms may also appear in other non-malignant diseases such as:
urinary tract infection, urinary bladder stones, benign tumors, and others. Only a physician can interpret these meaning of these symptoms; therefore, the appearance of any one of these presentations requires medical attention.
WINNER!
Wealth
Manager
of the Year
Treatment methods
The treatment of non-muscle invasive bladder cancer includes two main stages:
A) Surgical removal of all tumor(s) (under partial/general anesthesia) (TURBT). This is performed through the urethra, with no need to open the abdominal cavity. In case of numerous tumors, the doctor is compelled to perform successive TURBTs or an extensive operation.
Occasionally partial or complete removal of the urinary bladder is required (Cystectomy), especially when the tumor involves the muscle layer.
An alternative route for drainage of urine is then created. In cases of recurrent small tumors, it is possible to fulgurate their roots by laser (TUF), during cystoscopy.
B) After having ascertained the type of tumor and evaluation of the risk for recurrence and progression, preventive therapy is usually administered, by flushing the bladder with various chemically or biologically active materials (bladder instillations). Flushing with chemotherapeutic materials is intended to destroy cancer cells that were not removed during the operation or that have a high malignant potential. Biological flushing materials, such as BCG (tuberculosis bacteria) and others, are intended to create an immune response in the urinary bladder tissue, which leads to the destruction of cancer cells.
The doctor recommends the type of treatment or the combination of treatments based on the characteristics of the tumor(s) and the patient's condition. If there are several treatment options, the decision will be taken jointly by the doctor and the patient.
Diagnosing, defining the penetration (stage) and the aggressiveness (grade) of the disease
In order to identify the source of the symptoms, the doctor obtains general data concerning the patient's health and performs a physical examination. At a later stage, the doctor may use an instrument that enables direct visualization inside the urinary bladder during an exam called cystoscopy. During this procedure, it is possible to take tissue samples of the bladder wall (biopsy), for examination under the microscope. In case of suspicion of tumor during Cystoscopy, a surgical removal known as Transurethral Resection (TURBT) will normally follow. A tissue sample is usually necessary in order to characterize the tumor (grade) and the extent to which it has penetrated into the bladder wall (stage). The physician may eventually refer the patient for further medical investigation including: CT, MRI, ultrasound, X-rays of the urinary tract (IVP), etc.
